Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer.

Moore H, Huppert LA, Moslehi JJ, Yang EH, Hatcher S, Thomas A

Open source

DOI
10.1016/j.jaccao.2026.07.006
Published
2026 Aug
Container
JACC. CardioOncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jaccao.2026.07.006,
  title = {Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer.},
  author = {Moore H and Huppert LA and Moslehi JJ and Yang EH and Hatcher S and Thomas A},
  year = {2026},
  journal = {JACC. CardioOncology},
  doi = {10.1016/j.jaccao.2026.07.006},
  url = {https://doi.org/10.1016/j.jaccao.2026.07.006}
}

RIS

TY  - JOUR
TI  - Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer.
AU  - Moore H
AU  - Huppert LA
AU  - Moslehi JJ
AU  - Yang EH
AU  - Hatcher S
AU  - Thomas A
PY  - 2026
JO  - JACC. CardioOncology
DO  - 10.1016/j.jaccao.2026.07.006
UR  - https://doi.org/10.1016/j.jaccao.2026.07.006
ER  - 

APA

H, M., LA, H., JJ, M., EH, Y., S, H., & A, T. (2026). Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer.. JACC. CardioOncology. https://doi.org/10.1016/j.jaccao.2026.07.006

Source records